Marker for new blood vessel formation in tumors

In a paper in this month's freely-available online global health journal PLoS Medicine, Roland Haubner and colleagues describe how a compound they have developed can be used together with highly sensitive positron emission tomography (PET) scanning to measure the amount of new blood vessel growth in some tumors.

New blood vessel growth - angiogenesis - is important for the growth of tumors; several drugs target angiogenesis specifically. The compound previously developed by Haubner and colleagues is a fluorine-labeled glycopeptide, ([18F]Galacto-RGD), which binds tightly to a receptor - ávâ3 integrin -expressed in some tumors, especially in the blood vessels. As well as a role in angiogenesis, integrins are important in holding tumor cells together and connecting them with the extracellular matrix; what happens when these interactions break down is one of the keys to determining how tumors metastasize.

Haubner and colleagues' work, in a mouse with human melanoma and in a small study of patients with tumors including melanoma, suggests that the marker is truly reflecting the in vivo level of the integrin. Hence the marker could be used to identify tumors that express this marker, assess the degree of new vessel formation in tumors, and help in the planning and monitoring of anti-angiogenic therapies which target this integrin.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How a simple blood test can forecast future health risks